Literature DB >> 29736846

Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and/or local ablation.

Kim Sivesgaard1, Lars P Larsen2, Michael Sørensen3, Stine Kramer4, Sven Schlander2, Nerijus Amanavicius2, Arindam Bharadwaz2, Dennis Tønner Nielsen2, Frank Viborg Mortensen5, Erik Morre Pedersen2.   

Abstract

PURPOSE: To compare the diagnostic performance of contrast-enhanced computed tomography (CE-CT), magnetic resonance imaging (MRI) and combined fluorodeoxyglucose/positron emission tomography/computed tomography (FDG-PET/CT) for detection of colorectal liver metastases (CRLM) in patients eligible for local treatment.
MATERIALS AND METHODS: This health-research ethics-committee-approved prospective consecutive diagnostic accuracy study, with written informed consent, included 80 cases (76 patients, four participating twice) between 29 June 2015 and 7 February 2017. Prior chemotherapy or local treatment did not exclude participation. Combined FDG-PET/CT including CE-CT and MRI was performed within 0-3 days shortly before local treatment. CE-CT and MRI images were read independently by two readers for each modality. The combined FDG-PET/CT images were read independently by two pairs of readers. A composite reference standard was used. Sensitivities, specificities and area under the receiver operating characteristic curves (AUCROC) were calculated and compared.
RESULTS: In total, 260 CRLMs were confirmed. The MRI readers had significantly higher per-lesion sensitivity (85.9% and 83.8%) than both CE-CT readers (69.1% and 62.3%) and both PET/CT reader pairs (72.0% and 72.1%) (p<0.001). There were no significant differences in per-lesion specificity. MRI readers had significantly higher AUCROC (0.92 and 0.88) than both CE-CT readers (0.80 and 0.82) (p≤0.001). AUCROC for MR reader 1 was higher than that of both PET/CT reader pairs (0.83 and 0.84) (p≤0.0001).
CONCLUSION: MRI performed significantly better than both CE-CT and combined FDG-PET/CT for detection of CRLM in consecutive patients eligible for local treatment irrespective of prior chemotherapy or local treatment. KEY POINTS: • Patients eligible for local treatment of colorectal liver-metastases require optimal imaging. • In 80 consecutive patients, MRI had superior per lesion diagnostic performance. • Findings were independent of prior treatment and type of planned local treatment. • Equally, MRI had superior diagnostic performance on per segment basis.

Entities:  

Keywords:  Colorectal neoplasms; Computed tomography; Magnetic resonance imaging; Neoplasm metastasis; Positron emission tomography computed tomography

Mesh:

Substances:

Year:  2018        PMID: 29736846     DOI: 10.1007/s00330-018-5469-0

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  26 in total

1.  Diagnostic performance of CT, MRI and PET/CT in patients with suspected colorectal liver metastases: the superiority of MRI.

Authors:  Anselm Schulz; Ellen Viktil; Johannes Clemens Godt; Cathrine K Johansen; Johann Baptist Dormagen; Jon Erik Holtedahl; Knut Jørgen Labori; Tore Bach-Gansmo; Nils-Einar Kløw
Journal:  Acta Radiol       Date:  2015-11-29       Impact factor: 1.990

2.  Methods for calculating sensitivity and specificity of clustered data: a tutorial.

Authors:  Tessa S S Genders; Sandra Spronk; Theo Stijnen; Ewout W Steyerberg; Emmanuel Lesaffre; M G Myriam Hunink
Journal:  Radiology       Date:  2012-10-23       Impact factor: 11.105

3.  Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI?

Authors:  Vanessa Kulemann; Wolfgang Schima; Dietmar Tamandl; Klaus Kaczirek; Thomas Gruenberger; Friedrich Wrba; Michael Weber; Ahmed Ba-Ssalamah
Journal:  Eur J Radiol       Date:  2010-04-13       Impact factor: 3.528

4.  Comparison of gadoxetic acid-enhanced dynamic MR imaging and contrast-enhanced computed tomography for preoperative evaluation of colorectal liver metastases.

Authors:  Nobuyuki Asato; Masakatsu Tsurusaki; Keitaro Sofue; Yoko Hieda; Takashi Katsube; Kazuhiro Kitajima; Takamichi Murakami
Journal:  Jpn J Radiol       Date:  2017-03-01       Impact factor: 2.374

5.  Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis.

Authors:  An Tang; Justin Tan; Mark Sun; Gavin Hamilton; Mark Bydder; Tanya Wolfson; Anthony C Gamst; Michael Middleton; Elizabeth M Brunt; Rohit Loomba; Joel E Lavine; Jeffrey B Schwimmer; Claude B Sirlin
Journal:  Radiology       Date:  2013-02-04       Impact factor: 11.105

6.  Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation.

Authors:  A R Gillams; W R Lees
Journal:  Eur Radiol       Date:  2009-01-10       Impact factor: 5.315

7.  Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center.

Authors:  Waleed Shady; Elena N Petre; Mithat Gonen; Joseph P Erinjeri; Karen T Brown; Anne M Covey; William Alago; Jeremy C Durack; Majid Maybody; Lynn A Brody; Robert H Siegelbaum; Michael I D'Angelica; William R Jarnagin; Stephen B Solomon; Nancy E Kemeny; Constantinos T Sofocleous
Journal:  Radiology       Date:  2015-08-12       Impact factor: 11.105

8.  A meta-analysis of diffusion-weighted and gadoxetic acid-enhanced MR imaging for the detection of liver metastases.

Authors:  Valérie Vilgrain; Maxime Esvan; Maxime Ronot; Aurore Caumont-Prim; Christophe Aubé; Gilles Chatellier
Journal:  Eur Radiol       Date:  2016-02-16       Impact factor: 5.315

9.  Incremental value of liver MR imaging in patients with potentially curable colorectal hepatic metastasis detected at CT: a prospective comparison of diffusion-weighted imaging, gadoxetic acid-enhanced MR imaging, and a combination of both MR techniques.

Authors:  Hye Jin Kim; Seung Soo Lee; Jae Ho Byun; Jin Cheon Kim; Chang Sik Yu; Seong Ho Park; Ah Young Kim; Hyun Kwon Ha
Journal:  Radiology       Date:  2014-10-03       Impact factor: 11.105

10.  Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation.

Authors:  M Scharitzer; A Ba-Ssalamah; H Ringl; C Kölblinger; T Grünberger; M Weber; W Schima
Journal:  Eur Radiol       Date:  2013-03-22       Impact factor: 5.315

View more
  17 in total

1.  Radiomics analysis of contrast-enhanced CT for classification of hepatic focal lesions in colorectal cancer patients: its limitations compared to radiologists.

Authors:  Heejin Bae; Hansang Lee; Sungwon Kim; Kyunghwa Han; Hyungjin Rhee; Dong-Kyu Kim; Hyuk Kwon; Helen Hong; Joon Seok Lim
Journal:  Eur Radiol       Date:  2021-05-10       Impact factor: 5.315

2.  Clinical utility of [68Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma.

Authors:  Liang Zhao; Yizhen Pang; Hua Zheng; Chengkun Han; Jianwei Gu; Long Sun; Hua Wu; Sangang Wu; Qin Lin; Haojun Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04-01       Impact factor: 9.236

3.  Detection of liver metastases on gadobenate dimeglumine-enhanced MRI: systematic review, meta-analysis, and similarities with gadoxetate-enhanced MRI.

Authors:  Ling Zhang; Xian Yu; Lei Huo; Lun Lu; Xinpeng Pan; Ningyang Jia; Xinxiang Fan; Giovanni Morana; Luigi Grazioli; Guenther Schneider
Journal:  Eur Radiol       Date:  2019-03-26       Impact factor: 5.315

4.  Differentiation of histopathological growth patterns of colorectal liver metastases by MRI features.

Authors:  Wen-Hui Li; Shuai Wang; Yi Liu; Xin-Fang Wang; Yong-Feng Wang; Rui-Mei Chai
Journal:  Quant Imaging Med Surg       Date:  2022-01

5.  The potential utility of [68 Ga]Ga-DOTA-FAPI-04 as a novel broad-spectrum oncological and non-oncological imaging agent-comparison with [18F]FDG.

Authors:  Lianjun Lan; Hanxiang Liu; Yingwei Wang; Jia Deng; Dengsai Peng; Yue Feng; Li Wang; Yue Chen; Lin Qiu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-19       Impact factor: 9.236

Review 6.  Current state of the art imaging approaches for colorectal liver metastasis.

Authors:  Bita Hazhirkarzar; Pegah Khoshpouri; Mohammadreza Shaghaghi; Mounes Aliyari Ghasabeh; Timothy M Pawlik; Ihab R Kamel
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

7.  Clinical application of thioredoxin reductase as a novel biomarker in liver cancer.

Authors:  Xuping Wu; Qi Wang; Yousheng Lu; Jinye Zhang; Hanwei Yin; Yongxiang Yi
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

Review 8.  FDG-PET/CT imaging findings of hepatic tumors and tumor-like lesions based on molecular background.

Authors:  Kumi Ozaki; Kenichi Harada; Noboru Terayama; Nobuyuki Kosaka; Hirohiko Kimura; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2020-04-03       Impact factor: 2.374

9.  Development and assessment of an individualized nomogram to predict colorectal cancer liver metastases.

Authors:  Mingyang Li; Xueyan Li; Yu Guo; Zheng Miao; Xiaoming Liu; Shuxu Guo; Huimao Zhang
Journal:  Quant Imaging Med Surg       Date:  2020-02

10.  Dietary Melatonin and Glycine Decrease Tumor Growth through Antiangiogenic Activity in Experimental Colorectal Liver Metastasis.

Authors:  Mindaugas Kvietkauskas; Viktorija Zitkute; Bettina Leber; Kestutis Strupas; Philipp Stiegler; Peter Schemmer
Journal:  Nutrients       Date:  2021-06-13       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.